96 - Status Neutral Squabbles: Weight Gain on ART: Add a Weight-Loss Agent vs. Switch ART? And Should We Invest in nPEP as a Tool to EHE?

Thursday, October 17, 2024

3:15 PM – 4:30 PM US PT

Location: 515 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Interactive Moderator(s)

Charlotte-Paige Rolle, MD, MPH (she/her/hers)

Director of Research Operations
Orlando Immunology Center
Orlando, FL, United States
Darrell McBride, DO (he/him/his)

Physician
Geisinger Medical Center
Danville, PA, United States

Moderator(s)

Colleen Kelley, MD, MPH (she/her/hers)

Associate Professor of Medicine
Emory University
Decatur, GA, United States

Faculty(s)

Cecile Lahiri, MD, MS (she/her/hers)

Associate Professor
Emory University
Atlanta, GA, United States
Kristine Erlandson, MD MS (she/her/hers)

Professor
Department of Medicine, Divisions Infectious Diseases & Geriatric Medicine
University of Colorado Anschutz Medical Campus
Aurora, CO, United States
Darrell Tan, MD PhD (he/him/his)

Clinician-Scientist
Division of Infectious Diseases, Department of Medicine, St. Michael's Hospital
Toronto, ON, Canada
Latesha Elopre, MD (she/her/hers)

Assistant Professor of Medicine
University of Alabama of Birmingham
Birmingham, AL, United States

Disclosure(s):

Charlotte-Paige Rolle, MD, MPH: Gilead Sciences: Grant/Research Support, Honoraria; MSD: Grant/Research Support; ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria

Darrell McBride, DO: No financial relationships to disclose

Colleen F. Kelley, MD, MPH: Gilead Sciences: Grant/Research Support (Ongoing); Humanigen, Inc: Grant/Research Support (Terminated); Moderna, Inc.: Grant/Research Support (Terminated); Novavax, Inc.: Grant/Research Support (Terminated); ViiV Healtcare: Grant/Research Support (Ongoing)

Cecile D. Lahiri, MD, MS: Merck and Company, Inc.: Grant/Research Support (Terminated); Theratechnologies: Advisor/Consultant (Ongoing), Board Member (Ongoing)

Kristine M. Erlandson, MD MS: Gilead Sciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Terminated, November 30, 2022), Honoraria (Terminated, November 30, 2022); ViiV Healthcare/GSK: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Darrell H. S. Tan, MD PhD: Gilead Sciences: Grant/Research Support (Terminated); Glaxo Smith Kline: Grant/Research Support (Ongoing)

Latesha Elopre, MD: Merck and Company, Inc.: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe options for addressing weight gain in people with hiv;
explain the use of non-occupational post-exposure prophylaxis to reduce new hiv diagnoses.

Presentations:

3:15 PM – 3:33 PM US PT

Weight gain on ART: Switch ART
Debate Style Speaker: Cecile D. Lahiri, MD, MS (she/her/hers) – Emory University
3:33 PM – 3:51 PM US PT

Weight gain on ART: Add weight loss agent
Debate Style Speaker: Kristine M. Erlandson, MD MS (she/her/hers) – University of Colorado Anschutz Medical Campus
3:51 PM – 4:09 PM US PT

Should we invest in post-exposure prophylaxis (PEP) as a tool to end the HIV epidemic? Pro
Debate Style Speaker: Darrell H. S. Tan, MD PhD (he/him/his) – Division of Infectious Diseases, Department of Medicine, St. Michael's Hospital
4:09 PM – 4:30 PM US PT

Should we invest in non-occupational post-exposure prophylaxis (nPEP) as a tool to end the HIV epidemic? Con
Debate Style Speaker: Latesha Elopre, MD (she/her/hers) – University of Alabama of Birmingham